Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine

Ellen S. Vitetta; Joan E. Smallshaw; John Schindler

doi:10.1128/CVI.00381-12

Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine

Ellen S. Vitetta, Joan E. Smallshaw, John Schindler

Research output: Contribution to journal › Article › peer-review

44 Scopus citations

Abstract

There is no FDA-approved vaccine for the potent plant toxin ricin. We have developed a recombinant ricin vaccine, RiVax. Without adjuvant it is safe and immunogenic in mice, rabbits, and humans. Based on our studies in mice, we now report the results of a small clinical trial with Alhydrogel-adsorbed RiVax.

Original language	English (US)
Pages (from-to)	1697-1699
Number of pages	3
Journal	Clinical and Vaccine Immunology
Volume	19
Issue number	10
DOIs	https://doi.org/10.1128/CVI.00381-12
State	Published - Oct 2012

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Clinical Biochemistry
Microbiology (medical)

Access to Document

10.1128/CVI.00381-12

Cite this

@article{d170970f73b94332bf3977e01f2ab98e,

title = "Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine",

abstract = "There is no FDA-approved vaccine for the potent plant toxin ricin. We have developed a recombinant ricin vaccine, RiVax. Without adjuvant it is safe and immunogenic in mice, rabbits, and humans. Based on our studies in mice, we now report the results of a small clinical trial with Alhydrogel-adsorbed RiVax.",

author = "Vitetta, {Ellen S.} and Smallshaw, {Joan E.} and John Schindler",

year = "2012",

month = oct,

doi = "10.1128/CVI.00381-12",

language = "English (US)",

volume = "19",

pages = "1697--1699",

journal = "Clinical and Vaccine Immunology",

issn = "1556-6811",

publisher = "American Society for Microbiology",

number = "10",

}

TY - JOUR

T1 - Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine

AU - Vitetta, Ellen S.

AU - Smallshaw, Joan E.

AU - Schindler, John

PY - 2012/10

Y1 - 2012/10

N2 - There is no FDA-approved vaccine for the potent plant toxin ricin. We have developed a recombinant ricin vaccine, RiVax. Without adjuvant it is safe and immunogenic in mice, rabbits, and humans. Based on our studies in mice, we now report the results of a small clinical trial with Alhydrogel-adsorbed RiVax.

AB - There is no FDA-approved vaccine for the potent plant toxin ricin. We have developed a recombinant ricin vaccine, RiVax. Without adjuvant it is safe and immunogenic in mice, rabbits, and humans. Based on our studies in mice, we now report the results of a small clinical trial with Alhydrogel-adsorbed RiVax.

UR - http://www.scopus.com/inward/record.url?scp=84867241458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867241458&partnerID=8YFLogxK

U2 - 10.1128/CVI.00381-12

DO - 10.1128/CVI.00381-12

M3 - Article

C2 - 22914366

AN - SCOPUS:84867241458

SN - 1556-6811

VL - 19

SP - 1697

EP - 1699

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

IS - 10

ER -

Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this